Myeloproliferative Neoplasms: Integrating New Therapies Into Challenging Case Scenarios

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: September 14, 2020
Expiration Date: September 14, 2021

Expected time to complete this activity as designed: 75 minutes
There are no fees for participating in or receiving credit for this online activity.

This activity was previously presented as a webinar with live Q&A in September of 2020. Please note: If you participated in the live webinar, you are ineligible to receive an additional 1.25 contact hours of credit and may not re-submit for credit previously awarded.

Program Overview

Management of myeloproliferative neoplasms has evolved considerably since the identification of JAK2 and targeted therapy that has improved disease-related symptoms and quality of life. Our renowned faculty will provide updates in the latest data related to diagnosis, treatment options, guidelines, and standards of care through a highly interactive educational experience. Three real-life case scenarios will be presented, and the faculty will discuss treatment options and the journey of each patient.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurses, pharmacists and other allied healthcare professionals who provide care to patients with myeloproliferative neoplasms.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Summarize best practice strategies in molecular and mutational analysis in myeloproliferative neoplasms (MPNs), which assist in developing a patient-centered treatment approach
  • Articulate knowledge of new and emerging evidence in maintenance therapy as a new standard of care in MPNs
  • Outline guidelines and clinical trial evidence to identify appropriate treatment approaches for patients with MPNs
  • Describe strategies for identifying and managing treatment, including dosing and management of toxicities associated with novel and emerging therapies in MPNs

Agenda

Introduction – Prithviraj Bose, MD

Risk Stratification and Treatment Considerations in Polycythemia Vera and Myelofibrosis – Raajit K. Rampal, MD, PhD

Overcoming Clinical Challenges in MPNs: How Can We Improve Therapy? – Ruben Mesa, MD

Applying Knowledge Into Practice: Case Presentations – Prithviraj Bose, MD; Raajit K. Rampal, MD, PhD; Ruben Mesa, MD

Instructions for Participation and Credit

This activity is eligible for credit through September 14, 2021. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

Prithviraj Bose, MD
Associate Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Dr. Prithviraj Bose obtained his medical degree from the Calcutta Medical College at the University of Calcutta in Kolkata, India. He completed an internship in internal medicine at a University of Washington affiliate in Spokane, and residency at the Henry Ford Hospital in Detroit, followed by a fellowship in hematology and oncology at the University of Oklahoma Health Sciences Center in Oklahoma City. Dr. Bose is currently an Associate Professor in the Department of Leukemia at MD Anderson Cancer Center (MDACC), Houston, Texas.

Dr. Bose has published more than 250 peer-reviewed journal articles, book chapters, and scientific meeting abstracts. His work has appeared in The New England Journal of Medicine, Cancer Cell, Blood, Leukemia, Clinical Infectious Diseases and Williams’ Hematology. Additionally, he has served as a peer-reviewer for multiple hematology and oncology journals, including The New England Journal of Medicine, The Lancet Oncology, JAMA Oncology, Blood, and many others.

Dr. Bose’s major clinical and research focus is on myeloproliferative neoplasms (MPNs). He has presented his research at major international conferences such as the annual ASH and EHA meetings, authored numerous articles on MPN topics in peer-reviewed journals and books, and regularly speaks on MPN at national and regional meetings. He is also heavily involved in clinical trial design for patients with MPNs, and in other areas of MPN research. He is leading a number of important therapeutic clinical trials in myelofibrosis, polycythemia vera and systemic mastocytosis at MDACC. Dr. Bose represents MD Anderson on the MPN and systemic mastocytosis panels of the National Comprehensive Cancer Network.

Ruben Mesa, MD
Director
Mays Cancer Center
UT Health San Antonio
MD Anderson Cancer Center
San Antonio, Texas

Dr. Ruben Mesa received his medical degree from the Mayo Graduate School at the Mayo Clinic College of Medicine in Rochester, Minnesota. He completed his residency in internal medicine and his fellowship in hematology/medical oncology at Mayo. He is a fellow of the American College of Physicians and is certified by the American Board of Internal Medicine in internal medicine and medical oncology. Dr. Mesa is the Director at the Mays Cancer Center, the newly named center at UT Health San Antonio MD Anderson Cancer Center. The Mays Cancer Center is one of only four National Cancer Institute-designated Cancer Centers in Texas. For almost 30 years the cancer center has had a deep focus on providing world-class cancer care, advancing cancer research and educating the next-generation of cancer care scientists and care providers.

Dr. Mesa’s own practice builds on his role as an international expert on myeloproliferative neoplasms (MPNs), a group of bone marrow disorders that often lead to leukemia. He has been involved in MPN research for more than 20 years. He led the development of National Comprehensive Cancer Network’s panel guidelines, the first U.S. guidelines on the diagnosis and treatment of myelofibrosis, polycythemia vera, and essential thrombocythemia. Dr. Mesa has been the principal investigator or co-principal investigator of more than 70 clinical trials. He was the major research leader contributing to the FDA’s approval of ruxolitinib for polycythemia vera and myelofibrosis. He is currently leading the investigation of several other drugs for these types of cancers.

Raajit K. Rampal, MD, PhD
Assistant Member
Clinical Director, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, New York

Dr. Raajit Rampal is an Assistant Member at Memorial Sloan Kettering Cancer Center and Clinical Director of the Leukemia Service. The focus of his research has been to utilize genetic insights from primary patient samples to elucidate mechanism of pathogenesis in acute myeloid leukemia (AML) and the Philadelphia-chromosome negative myeloproliferative neoplasms (MPN). These genetic insights are being used to develop novel models of AML and MPN, and to develop mechanism-based clinical trials.

Accreditation

MediCom Worldwide, Inc. CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.25 contact hours of Continuing Education Credit.
Universal Activity Number: 827-0000-20-036-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.

MediCom Worldwide, Inc. NURSING CREDIT
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.25 contact hours. Program Number: 20-036-129

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. Prithviraj Bose has received honoraria related to formal advisory activities from Incyte Corporation, Celgene Corporation - A Bristol-Myers Squibb Company, CTI BioPharma Corp., and Kartos Therapeutics, Inc., as well as consultant fees from Incyte. He has received grant support related to research activities from Astellas Pharma US, Inc., Blueprint Medicines, Celgene, Constellation Pharmaceuticals, CTI BioPharma, Incyte, Kartos Therapeutics, NS Pharma, Inc., Pfizer Inc., and Promedior, Inc.

Dr. Ruben Mesa has received honoraria as a consultant from La Jolla Pharmaceutical Company, Novartis AG, and Sierra Oncology, Inc. He has received grant support related to research activities from AbbVie Inc., Celgene Corporation - A Bristol-Myers Squibb Company, CTI BioPharma Corp., Genentech, Inc., Incyte Corporation, Promedior, Inc., and Samus Therapeutics, Inc.

Dr. Raajit Rampal has received honoraria related to formal advisory activities, as well as consultant fees from AbbVie Inc., Blueprint Medicines, Celgene Corporation - A Bristol-Myers Squibb Company, CTI BioPharma, Galecto Biotech, Incyte Corporation, Jazz Pharmaceuticals plc, Kartos Therapeutics, and PharmaEssentia Corporation. He has received grant support related to research activities from Constellation Pharmaceuticals, Incyte, and Stemline Therapeutics, Inc.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, Wilma Guerra, Program Director, and Andrea Mathis, Project Manager, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at [email protected]

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb and Incyte Corporation.

©2020 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.